Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nanologica AB's Enterprise Value is kr235.63 Mil.
Nanologica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-26.95 Mil. Therefore, Nanologica AB's EV-to-FCF for today is -8.74.
The historical rank and industry rank for Nanologica AB's EV-to-FCF or its related term are showing as below:
OSTO:NICA'
s EV-to-FCF Range Over the Past 10 Years
Min: -24.08 Med: -4.59 Max: -0.44
Current: -8.62
During the past 12 years, the highest EV-to-FCF of Nanologica AB was -0.44. The lowest was -24.08. And the median was -4.59.
OSTO:NICA's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs OSTO:NICA: -8.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanologica AB's PE Ratio (TTM) for today is calculated as:
Nanologica AB's share price for today is kr0.474.
Nanologica AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.274.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nanologica AB EV-to-FCF Related Terms
Nanologica AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nanologica AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Nanologica AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nanologica AB's EV-to-FCF falls into.
Nanologica AB's current Enterprise Value is kr235.63 Mil.
Nanologica AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-26.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a EV-to-FCF of -8.74 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #999999 out of 335 companies in the Biotechnology industry.
Is Nanologica AB's EV-to-FCF too high?
Nanologica AB's current EV-to-FCF is -8.74. Based on the distribution chart, Nanologica AB ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #999999 out of 335 companies for EV-to-FCF. This places Nanologica AB in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanologica AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current EV-to-FCF is -8.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current EV-to-FCF is -8.74. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current EV-to-FCF is -8.74 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
EV-to-FCF: -8.74
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
